ISX:CARE has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ISX:CARE has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
PT Metro Healthcare Indonesia Tbk ISX:CARE
PT Metro Healthcare Indonesia Tbk ISX:CARE 71 EV-to-EBIT is 142.20 as of Aug. 29, 2026, which is 9% below its 10-year median of 156.83. GuruFocus rates ISX:CARE with a GF Score™ of 71/100 and a GF Value™ of Rp367.51 (Modestly Overvalued). The stock has 2 warning signs investors should review. Among 480 Healthcare Providers & Services companies, PT Metro Healthcare Indonesia Tbk ranks worse than 95.63% on this metric.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, PT Metro Healthcare Indonesia Tbk's Enterprise Value is Rp15,356,536 Mil. PT Metro Healthcare Indonesia Tbk's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was Rp107,995 Mil. Therefore, PT Metro Healthcare Indonesia Tbk's EV-to-EBIT for today is 142.20.
The historical rank and industry rank for PT Metro Healthcare Indonesia Tbk's EV-to-EBIT or its related term are showing as below:
During the past 10 years, the highest EV-to-EBIT of PT Metro Healthcare Indonesia Tbk was 6092.36. The lowest was -6370.14. And the median was 156.83.
Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. PT Metro Healthcare Indonesia Tbk's Enterprise Value for the quarter that ended in Jun. 2026 was Rp14,359,036 Mil. PT Metro Healthcare Indonesia Tbk's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was Rp107,995 Mil. PT Metro Healthcare Indonesia Tbk's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2026 was 0.75%.
PT Metro Healthcare Indonesia Tbk (ISX:CARE) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.
PT Metro Healthcare Indonesia Tbk's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2026 is calculated as:
| Earnings Yield (Joel Greenblatt) % (Q: Jun. 2026 ) | = | EBIT | / | Enterprise Value (Q: Jun. 2026 ) |
| = | 107994.562 | / | 14359035.605 | |
| = | 0.75 % |
PT Metro Healthcare Indonesia Tbk's Enterprise Value for the quarter that ended in Jun. 2026 was Rp14,359,036 Mil.
PT Metro Healthcare Indonesia Tbk's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was Rp107,995 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The historical data trend for PT Metro Healthcare Indonesia Tbk's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
| PT Metro Healthcare Indonesia Tbk Annual Data | |||||||||||||||||||||
| Trend | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | Dec25 | |||||||||||
| EV-to-EBIT | Get a 7-Day Free Trial |
|
|
525.27 | -4,000.02 | -181.92 | -5,621.21 | 274.54 | |||||||||||||
| PT Metro Healthcare Indonesia Tbk Quarterly Data | ||||||||||||||||||||
| Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | Mar25 | Jun25 | Sep25 | Dec25 | Mar26 | Jun26 | |
| EV-to-EBIT | Get a 7-Day Free Trial |
|
|
|
|
|
|
|
|
|
|
|
|
224.02 | 151.78 | 274.54 | 114.86 | 132.96 | ||
For the Medical Care Facilities subindustry, PT Metro Healthcare Indonesia Tbk's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Healthcare Providers & Services industry and Healthcare sector, PT Metro Healthcare Indonesia Tbk's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where PT Metro Healthcare Indonesia Tbk's EV-to-EBIT falls into.
PT Metro Healthcare Indonesia Tbk's EV-to-EBIT for today is calculated as:
| EV-to-EBIT | = | Enterprise Value (Today) | / | EBIT (TTM) |
| = | 15356535.605 | / | 107994.562 | |
| = | 142.20 |
PT Metro Healthcare Indonesia Tbk's current Enterprise Value is Rp15,356,536 Mil.
PT Metro Healthcare Indonesia Tbk's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was Rp107,995 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Based on GuruFocus' analysis, PT Metro Healthcare Indonesia Tbk stock appears to be overvalued. The current stock price of Rp444.00 is trading 20.8% above its estimated GF Value™ of Rp367.51. GuruFocus considers PT Metro Healthcare Indonesia Tbk to be Modestly Overvalued.
Key valuation signals for ISX:CARE:
No single metric tells the full story. See the ISX:CARE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.